Stratec Se Stock

Stratec Se FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Stratec Se (SBS.DE) as of Aug 15, 2026 is 4,012.81 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 190.52 % — a change of 2,006.25% (higher).

FCF Conversion

4,012.81 %

YoY

2,006.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Stratec Se is 2026 4,012.81 % . FCF Conversion Rate (FCF/EBITDA) of Stratec Se was 2025 190.52 % . It decreases by 2,006.25% higher compared to the previous year.
Access this data via the Eulerpool API

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stratec Se stock

FCF Conversion Rate (FCF/EBITDA) of Stratec Se is 4,012.81 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Stratec Se changed from 190.52 % to 4,012.81 %, representing a 2,006.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Stratec Se since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Stratec Se with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Stratec Se

All Key Metrics — Stratec Se